BC Extra | Oct 24, 2019
Financial News

Oct. 23 Financial Quick Takes: Alexion buyback; plus RAPT, NeuroRX and Oyster Point

Billion-dollar buyback for Alexion  The board of Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) has approved a $1 billion share repurchase authorization, with no expiration date. Alexion announced the buyback with its 3Q19 earnings, in which it reported...
BC Week In Review | Jan 11, 2019
Clinical News

NeuroRx's NRX-101 improves depression and suicidality in Phase II

NeuroRx Inc. (Wilmington, Del.) said NRX-101 improved depression and suicidality in the Phase II STABIL-B trial to treat severe bipolar depression and acute suicidal ideation and behavior. Data were presented in December at the American...
BC Week In Review | Jan 5, 2017
Clinical News

NRX-101: Ph IIb/III started

NeuroRx began a double-blind Phase IIb/III trial to compare twice-daily oral NRX-101 containing 175 or 237.5 mg D-cycloserine and 8.25, 16.5 or 33 mg lurasidone vs. Latuda lurasidone for up to 6 weeks in about...
Items per page:
1 - 3 of 3